CSIMarket Company Name, Ticker, Competitors, else..
 
Arca Biopharma Inc  (ABIO)
Other Ticker:  
 
 
Price: $2.4000 $-0.10 -4.000%
Day's High: $2.47 Week Perf: -37.01 %
Day's Low: $ 2.22 30 Day Perf: -18.92 %
Volume (M): 289 52 Wk High: $ 4.49
Volume (M$): $ 695 52 Wk Avg: $2.61
Open: $2.35 52 Wk Low: $1.56



 Market Capitalization (Millions $) 36
 Shares Outstanding (Millions) 15
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -34
 Cash Flow (TTM) (Millions $) 413
 Capital Exp. (TTM) (Millions $) 0

Arca Biopharma Inc
Arca Biopharma Inc is a biopharmaceutical company that focuses on the development and commercialization of treatments for cardiovascular diseases. The company primarily focuses on developing genetically-targeted therapies, using its proprietary technology to identify and select patients who are most likely to benefit from certain treatments. Arca Biopharma aims to improve the effectiveness and safety of current treatment options for cardiovascular diseases, such as heart failure and atrial fibrillation. They collaborate with leading academic institutions and research organizations to advance their drug development programs.


   Company Address: 10170 Church Ranch Way Westminster 80021 CO
   Company Phone Number: 940-2100   Stock Exchange / Ticker: NASDAQ ABIO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BZYR      % 
CLDX        1.36% 
AMGN   -5.18%    
BCRX        2.6% 
NVAX        8.56% 
REGN        1.3% 
• View Complete Report
   



Merger and Acquisition

The Combined Future: Arca Biopharma Inc Merges with Oruka Therapeutics, Inc and Takes the Nasdaq by Storm

Published Thu, Aug 29 2024 8:50 PM UTC

The Combined Future: Arca Biopharma Inc. Merges with Oruka Therapeutics, Inc. and Takes the Nasdaq by Storm
In a significant move poised to reshape the landscape of precision medicine for cardiovascular diseases, Arca Biopharma Inc. (NASDAQ: ABIO) has successfully completed its merger with Oruka Therapeutics, Inc. The newly formed entity will operate under the name Oruk...
Dividend

ARCA Biopharma Announces Attractive Special Dividend Amid Merger With Oruka Therapeutics: A Boost for Investors,

Published Mon, Aug 26 2024 11:30 PM UTC



ARCA Biopharma s Special Dividend Amid Merger Talks: What Investors Need to Know
On August 26, 2024, ARCA biopharma, Inc. (NASDAQ: ABIO) released a press statement announcing a special dividend of $1.613 per share of common stock, which is to be distributed on August 28, 2024. This dividend is a notable component of the company s forthcoming merger with Oruka ...
Merger and Acquisition

ARCA biopharma Reports Strong First Quarter 2024 Results and Unveils Promising Corporate Developments

Published Thu, Apr 25 2024 8:15 PM UTC


ARCA biopharma Inc, a leader in In Vitro & In Vivo Diagnostic Substances, recently announced their financial results for the first quarter of 2024. The company reported a market capitalization of $42 million, showcasing their strong position in the industry.
During the first quarter, ARCA biopharma saw significant growth in revenue and profits, demonstrating the eff...
Clinical Study

Advancing Treatment for Chronic Skin Diseases: The ARCA biopharma and Oruka Therapeutics Merger Agreement

Published Wed, Apr 3 2024 11:30 AM UTC

The recent merger agreement between ARCA biopharma and Oruka Therapeutics has paved the way for a new era in the treatment of chronic skin diseases. This anticipated merger aims to harness Oruka's innovative portfolio of novel biologics to redefine the standard of care for patients suffering from these debilitating conditions. This article delves into the facts surrounding t...
Arca Biopharma Inc

Arca Biopharma Inc Surges in Q3 2023, Delivering Positive News for Investors with a Decreased Operating Shortfall

Over the past five days, the stock of Arca Biopharma Inc has experienced a slight decrease of -0.25%. This decline contributes to a year-to-date performance of -15.91%, indicating a challenging period for the company's stock value. However, it is worth noting that despite this decrease, Arca Biopharma Inc's stock is still trading 10% above its lowest point in the past 52 weeks.
During the current earnings season, which encompasses the period from July to September 30, 2023, numerous corporations across various sectors have been announcing their financial results. Within the In Vitro & In Vivo Diagnostic Substances sector, Arca Biopharma Inc is one of the entities that have disclosed their performance.
Arca Biopharma Inc recently reported an operating shortfall of $-1.937 million for the fiscal interval ending on September 30, 2023. Compared to the third quarter of 2022, where the operating shortfall reached $-2.552 million, this is an improvement and a positive signal for the state of the company. Examining the numbers in more detail, the deficit has decreased from $-2.333 million in the third quarter of 2022 to $-1.424 million in the same period this year. This decline in the shortfall is a promising revelation and indicates progress towards a more successful future for Arca Biopharma Inc.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com